Ho M. Kim
Itami, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Clinical Impact of Two-Week Placement of a Subcutaneous Suction Drain in Preventing Incisional Surgical Site Infection in Open Gastrointestinal Surgery with Class 4 Dirty Wound: A Retrospective Study.
Journal: Surgical infections
Published: September 07, 2022
Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen.
Journal: Anticancer research
Published: March 04, 2022
Capecitabine and Oxaliplatin(CAPOX)plus Bevacizumab as Second-Line Chemotherapy for Metastatic Colorectal Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: April 01, 2021
Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study.
Journal: The oncologist
Published: November 02, 2020
Laparoscopic surgery for idiopathic adult intussusception successfully reduced by colonoscopy.
Journal: Journal of the anus, rectum and colon
Published: July 18, 2018
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
Journal: Cancer chemotherapy and pharmacology
Published: December 15, 2017
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study.
Journal: Cancer chemotherapy and pharmacology
Published: December 14, 2017
Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 20, 2017
Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.
Journal: Cancer chemotherapy and pharmacology
Published: September 29, 2016
Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial.
Journal: Cancer chemotherapy and pharmacology
Published: July 06, 2016
A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).
Journal: Clinical colorectal cancer
Published: March 01, 2016
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.
Journal: International journal of clinical oncology
Published: February 15, 2016
Last Updated: 09/26/2026